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Drug-coated balloons (DCBs) are used to treat various cardiovascular diseases. Currently available DCBs
carry drug on the balloon surface either solely or using different carriers. Several studies have shown that
a significant amount of drug is lost in the blood stream during balloon tracking to deliver only a sub-
therapeutic level of drug at the treatment site. This research is focused on developing paclitaxel (PAT)
loaded polyethylene oxide (PEO) films (PAT–PEO) as a controlled drug delivery carrier for DCBs. An array
of PAT–PEO films were developed in this study to provide tailored release of >90% of drug only at specific
time intervals, which is the time frame required for carrying out balloon-based therapy. The characteri-
zations of PAT–PEO films using SEM, FTIR, and DSC showed that the films developed were homogenous
and the PAT was molecularly dispersed in the PEO matrix. Mechanical tests showed that most PAT–PEO
films developed were flexible and ductile, with yield and tensile strengths not affected after PAT incor-
poration. The viability, proliferation, morphology, and phenotype of smooth muscle cells (SMCs) inter-
acted with control-PEO and PAT–PEO films were investigated. All control-PEO and PAT–PEO films
showed a significant inhibitory effect on the growth of SMCs, with the degree of inhibition strongly
dependent on the w/v% of the polymer used. The PAT–PEO coating was produced on the balloons. The
integrity of PAT–PEO coating was well maintained without any mechanical defects occurring during bal-
loon inflation or deflation. The drug release studies showed that only 15% of the total PAT loaded was
released from the balloons within the initial 1 min (typical balloon tracking time), whereas 80% of the
PAT was released between 1 min and 4 min (typical balloon treatment time). Thus, this study demon-
strated the use of PEO as an alternate drug delivery system for the balloons.
Statement of Significance
Atherosclerosis is primarily responsible for cardiovascular diseases (CVDs) in millions of patients every
year. Drug-coated balloons (DCBs) are commonly used to treat various CVDs. However, in several cur-
rently used DCBs, a significant amount of drug is lost in the blood stream during balloon tracking to deli-
ver only a sub-therapeutic level of drug at the treatment site. In this study, paclitaxel containing
polyethylene oxide (PEO) films were developed to provide unique advantages including drug release pro-
files specifically tailored for balloon-based therapy, homogeneous films with molecularly dispersed drug,
flexible and ductile films, and exhibits significant inhibitory effect on smooth muscle cell growth. Thus,
this study demonstrated the use of PEO as an alternate drug delivery platform for DCBs to improve its
efficacy.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-coated balloons (DCBs) are currently used to treat various
cardiovascular diseases by opening up the blocked arteries and
delivering antiproliferative therapeutic drugs locally to prevent
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able are coated with drugs either directly without using any carri-
ers (a carrier is a substance that provides a platform to carry drug
on the balloon surface and to deliver it in a controlled manner) or
using different types of carriers [11,12]. The carriers that are cur-
rently used in DCBs include urea, polysorbate emulsifier, shellac
resin, iopromide contrast medium, and butyryl trihexyl citrate
plasticizer [11,12]. Most of these carriers are chosen on the basis
of their usefulness to improve drug penetration into the tissue
and not on whether they assist in delivering significant amount
of drug at the treatment site of diseased portion of the artery.
The major limitation of currently available DCBs is the delivery
of drug from the balloons is not controlled effectively in order to
avoid drug loss during balloon tracking and to rapidly deliver a
therapeutic level of drug at the treatment site [11–14]. It has been
reported that a significant amount of drug (up to 80%) is lost in the
blood stream even before the balloon is tracked to the treatment
site [11–14]. Also, during the short balloon inflation time
(2–3 min), the drug is not rapidly transferred from the balloon to
the tissue [11–14]. Hence, in many cases, only a subtherapeutic
level of drug is delivered at the treatment site [11–14]. Therefore,
a great need has arisen to control the delivery of drug from the bal-
loons in such a way that the drug loss during its transit to the treat-
ment site should be as minimal as possible, and then, all or most of
the drug from the balloon should be immediately released at the
treatment site during the short time of balloon inflation. With this
as the goal, in this study, we have developed paclitaxel (PAT)
loaded polyethylene oxide (PEO) films to provide drug release pro-
files that are well-suited for use in DCBs. The w/v% of PEO and wt%
of PAT were varied to obtain different groups of PAT–PEO films that
show tailored release of >90% of drug only at specific time inter-
vals. The various PAT–PEO films developed in this study were char-
acterized for their drug loading and release profiles, surface and
bulk properties, mechanical properties, and smooth muscle cell
(SMC) growth inhibitory effects. Also, the PAT–PEO coating pro-
duced on the balloons was investigated for its coating integrity
and drug release properties. The results of PAT–PEO coated bal-
loons were then compared to that of control DCBs, which were pre-
pared using PAT only (without any carriers) and currently used
drug–carrier combinations such as PAT–urea, PAT–polysorbate/sor
bitol, PAT–shellac, and PAT–contrast agent.2. Materials and methods
2.1. Materials
Poly(ethylene oxide) (PEO, average Mv 100,000), ethanol (200
proof), methanol, phosphate-buffered saline with 0.05 wt% tween-
20 (PBS/T-20), Dulbecco’s phosphate-buffered saline (DPBS), fluo-
rescein diacetate (FDA), tris-buffered saline (TBS), propidium iodide
(PI), HPLC-grade water and acetonitrile, urea, polysorbate, sorbitol,
and shellacwere all purchased fromSigma–Aldrich (USA). Iodixanol
(contrast agent) was purchased from GE Healthcare Inc. (Princeton,Table 1A
Polymer weight, solvent volume, drug solution volume, and stirring speed used in the pre
PAT–PEO film groups PEO (wt/vol%) PAT (wt%) Weight
of PEO (grams)
V
of
PAT–PEO-10 10 1.5 2 17
PAT–PEO-15 15 1 3 17
PAT–PEO-20 20 0.75 4 17
PAT–PEO-25 25 0.6 5 17
* Stirring speed was decided depending on the viscosity of the solution. For instance, a
However, for PAT–PEO-25, which is highly viscous when compared to other PAT–PEO soNJ). Paclitaxel (PAT) was purchased from ChemieTek (Indianapolis,
IA). All chemicals purchased were used as received.
2.2. Preparation of PAT loaded PEO films and control PEO films
PAT loaded PEO (PAT–PEO) films were prepared in this study
using the solvent casting method. Initially, the PEO (10%, w/v)
was dissolved in de-ionized water (di-H2O) by stirring the polymer
in the solvent at 200 rpm for 6 h. In parallel, a solution of PAT was
prepared in ethanol by sonicating the drug in the solvent for 5 min
thrice. The PAT solution (10 mg/mL) prepared was then added
dropwise into the PEO solution at 1.5 wt%, and the drug-polymer
mixture was stirred at 200 rpm for 18 h. The drug-polymer mix-
ture solution was then poured into a petridish (8.8 cm in diameter)
and heated in an oven at 50 C under vacuum (20 inHg) for 48 h.
The oven was then turned off and the samples were left inside the
oven for 30 min to slowly cool the samples. The petridish was then
removed from the oven and the PAT–PEO films formed were peeled
off using a razor. The PAT–PEO films were then cut into specimens
of varying sizes for performing different characterizations.
Similar experiments were carried out for preparing PAT–PEO
films with 15, 20, and 25 w/v% of PEO. However, there was no
change made in the concentration (10 mg/mL) or volume (3 mL)
of PAT solution that was added to the different w/v% PEO. This
led to PAT loadings of 1.0, 0.75, and 0.6 wt% in PEO (15%, w/v),
PEO (20%, w/v), and PEO (25%, w/v) films, respectively. Thus, the
PAT–PEO films prepared in this study with 10 w/v% of PEO and
1.5 wt% of PAT, 15 w/v% of PEO and 1.0 wt% of PAT, 20 w/v% of
PEO and 0.75 wt% of PAT, and 25 w/v% of PEO and 0.6 wt% of
PAT are referred to as PAT–PEO-10, PAT–PEO-15, PAT–PEO-20,
and PAT–PEO-25, respectively. Table 1A shows the polymer
weight, solvent volume, drug solution volume, and stirring speed
used in the preparation of these four different groups of PAT–
PEO films.
Control PEO films (without PAT loaded) were also prepared at
four different w/v% (10, 15, 20, and 25). The protocols for preparing
these control films were similar to the above mentioned procedure
without the addition of PAT (Table 1B).
2.3. Drug-elution studies
For the drug-elution studies, the PAT–PEO film specimens
(0.5 cm  0.5 cm) were immersed in 25 mL of PBS/T-20 solution
and incubated in a circulating water bath (Thermo Scientific,
USA) at 37 C. As a standard protocol, Tween-20, a non-ionic sur-
factant, was added in the release medium to increase the solubility
of PAT in PBS and to maintain sink conditions [15,16]. At each pre-
determined time point (30 s, 1 min, 2 min, 3 min, 5 min, and
7 min), the films were taken out of the solution and transferred
to a fresh PBS/T-20 solution. Due to the inherent water solubility
of PEO, the films started to turn loose at different time points
depending on the group of PAT–PEO film. When the films turned
too loose to handle at a time point, it was permanently placed in
the PBS/T-20 solution used for that respective time point withoutparation of four different groups of PAT–PEO films.
olume
di-H2O (mL)
Volume of PAT solution in mL
(drug concentration is 10 mg/mL)
Stirring speed* during
mixing (rpm)
3 200
3 200
3 175
3 50
stirring speed of 200 rpm was required for an even mixing of PAT–PEO-10 solution.
lutions, the stirring speed has to be significantly reduced to 50 rpm for even mixing.
Table 1B
Polymer weight, solvent volume, and stirring speed used in the preparation of four different groups of control PEO films.
Control PEO film groups PEO (wt/vol%) PAT (wt%) Weight of PEO
(grams)
Volume
of di-H2O (mL)
Volume of PAT solution in mL
(drug concentration is 10 mg/mL)
Stirring speed during
mixing (rpm)
PEO-10 10 0 2 20 0 200
PEO-15 15 0 3 20 0 200
PEO-20 20 0 4 20 0 175
PEO-25 25 0 5 20 0 50
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film was permanently placed in the PBS/T-20 solution was
regarded as the final time point for that particular group of PAT–
PEO film. The final time points for PAT–PEO-10, PAT–PEO-15,
PAT–PEO-20, and PAT–PEO-25 groups were 2 min, 5 min, 5 min,
and 7 min, respectively. The PBS/T-20 samples collected at each
time point were then used for determining the amount of PAT
released using high performance liquid chromatography (HPLC).
Prior to HPLC analysis, 1 mL of ethanol was added to the plastic
tubes in which the PBS/T-20 samples were collected and shaken
well for 30 s. This ethanol addition step was carried out as a stan-
dard procedure to remove any PAT that was physically bound to
the plastic tube surfaces [15,16]. The HPLC method for determining
PAT released was carried out as we reported previously [17,18].
2.4. Characterization of PAT–PEO and control PEO films
All PAT–PEO and control PEO films prepared in this study were
characterized using scanning electron microscopy (SEM), optical
surface profilometry (OSP), Fourier transform infrared spec-
troscopy (FTIR), and differential scanning calorimetry (DSC). A
Quanta 450 SEM (FEI, USA) was used to image the morphology of
surfaces as well as the cross-sections of PAT–PEO and control
PEO films. For SEM imaging, 10 kV and 30 kV accelerating voltages
were used for obtaining surface and cross-sectional images,
respectively. Prior to SEM analysis, the films were sputter-coated
with a 15 nm thick gold–palladium to avoid surface charging. A
Wyko NT8000 OSP (Bruker Corporation; operated at Michigan
Metrology, LLC) was used in this study to obtain 3D topography
images of control PEO and PAT–PEO specimens. A Nicolet 6700
FTIR spectroscopy (Thermo Scientific, USA) equipped with an
attenuated total reflection (ATR) accessory was used to character-
ize the surfaces of PAT–PEO and control PEO films. The FTIR spectra
of PAT and PEO in powder forms were also obtained. All FTIR spec-
tra were collected at 1024 scans with a spectral resolution of
4 cm1. All collected spectra were analyzed using OMNIC software.
A Q200 DSC (TA instruments, New Castle, DE) was used in this
study to characterize all PAT–PEO and control PEO films. PEO and
PAT in powder forms were also characterized using DSC. For this
characterization, a sample weighing 8–10 mg was sealed in an alu-
minum plan and heated to 300 C at a scan rate of 10 C/min. As a
reference, an empty aluminum pan was used. All DSC measure-
ments were carried out under nitrogen gas at a flow rate of
40 mL/min.
2.5. Mechanical testing of PAT–PEO and control PEO films
An MTS insight electromechanical instrument (MTS System
Corp., Eden Prairie, MN) was used in this study to characterize all
PAT–PEO and control PEO film specimens (1 cm  7 cm, n = 3 for
each sample group). The thickness of the specimens was deter-
mined using SEM. The specimens were gripped at a length of
1 cm from each end and stretched to failure using a 100N load cell
at 50 mm/min extension rate. A TestWorks 4 software was used to
determine the elastic modulus, strain at break, peak load, and ten-
sile strength from the stress–strain curves obtained for the films.2.6. Characterization of PAT–PEO films post drug-elution studies
To determine the drug delivery mechanism, the PAT–PEO films
used in the drug-elution studies were characterized using FTIR and
DSC to observe the changes occurred in the chemical composition
and crystallinity of the films, respectively. Also, the films were
immersed in 2 mL of PBS/T-20 at 37 C, and real-time images were
obtained using phase contrast microscopy to observe the morpho-
logical changes of the films.
2.7. Smooth muscle cell (SMC) cultures
Human aortic smooth muscle cells (HASMCs, catalog No. 354-
05a) and smooth muscle cell growth medium (catalog No. 311-
500) were obtained from Cell Applications (San Diego, CA). The
cells were cultured in the growth medium at 37 C in a humidified
5% CO2 incubator. The cells obtained from passages four to six were
used in this study. Initially, a density of 15  103 cells (in 1000 lL
of growth medium) was allowed to grow in the wells of a 24-well
tissue culture plate for 24 h. The used media were then removed
and 1000 lL of fresh growth media were added to the wells. Then,
PAT–PEO or control-PEO film specimens (1 cm  1 cm) were added
to the cells grown in the wells. After 18 h (on day-1), the used
media were removed and 1000 lL of fresh growth media were
added to the wells. The media were changed again on day-3 and
day-5. A control experiment was also carried out as the cells were
allowed to grow in the wells in the absence of either PAT–PEO or
control-PEO films.
2.7.1. Smooth muscle cell viability and proliferation
The resazurin cell viability assay kit (trademark name Ala-
marBlue) was purchased from Biotium (Hayward, CA) and used
to quantitatively measure the viability and proliferation of cells
[19,20]. At pre-determined time points (day-1, 3, and 5), the used
media were removed and a solution containing the mixture of
resazurin (100 lL) and cell culture medium (900 lL) was added
to the cells. Then, the cells were incubated in the solution at
37 C in the dark for 6 h. The fluorescence of the solution was mea-
sured using a Tecan Infinite M200 microplate reader (Tecan
Group Ltd., Mannedorf, Switzerland) at excitation and emission
wavelengths of 530 nm and 590 nm, respectively. The fluorescence
of the blanks (cell growth medium and resazurin, without cells)
was also obtained and the value was subtracted from the fluores-
cence values of the experimental samples. The values reported
here are the corrected fluorescence values. For the cell viability
and proliferation study, three samples were used for each of the
eight groups (four groups of PAT–PEO and four groups of control
PEO) at each time point (1, 3, and 5 days). Therefore, 72 samples
were used in this part of the study.
2.7.2. Smooth muscle cell morphology
The morphology of SMCs was characterized as we reported pre-
viously [19,20]. Briefly, a stock solution of fluorescein diacetate
(FDA) was prepared at a concentration of 1 mg/mL in acetone.
The working solution was prepared by adding 100 lL of the pre-
pared FDA stock solution to 900 lL of DPBS. After 1, 3, and 5 days,
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the FDA working solution and 1000 lL of DPBS was added to the
cells. Then, the cells were incubated in the solution at 20 C in
the dark for 15 min. An Axiovert 200 M inverted fluorescence
microscope (Carl Zeiss Microscopy, Thornwood, NY) was used to
image the cells. For the morphology study also, three samples were
used for each of the eight sample groups at each of the three time
points. Hence, 72 samples were used for this part of the study as
well. The fluorescence images were obtained at a minimum of four
different spots on each sample and the representative images of
each sample group are provided here. The SMC size was quantita-
tively determined by calculating its aspect ratio using the ImageJ
software. The aspect ratio of cells was defined as the ratio of length
of major axis to the length of minor axis, with 1.0 being a complete
circle. For each experimental group at each time point, three
images were used for analysis. In each image, an aspect ratio of
at least 10 cells was calculated. Hence, a total of 30 cells per group
per time point was measured for the analysis.
2.7.3. Smooth muscle cell phenotype
Triton X-100, goat serum, a-actin antibody (1A4), and goat anti-
mouse IgG-FITC were all purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The SMC phenotype was characterized as we
reported previously [20]. Briefly, the cells treated with control
PEO films or PAT–PEO films or no films (control wells) were
allowed to grow for 3 days. Then, the cells were washed with DPBS
twice and fixed using 4% paraformaldehyde (Affymetrix, Santa
Clara, CA) at room temperature (RT) for 10 min. The cells were then
washed with DPBS five times for 3 min each and incubated in a
permeabilizing solution (0.1% Triton X-100 in tris-buffered saline)
for 25 min at RT. The cells were subsequently washed with DPBS
followed by incubating in blocking buffer (10% of goat serum in
permeabilizing solution) for 25 min at RT. Then, the cells were
washed with DPBS and incubated in a-actin primary antibody
diluted 1:50 with 1.5% goat serum in DPBS for 90 min at RT. After
washing with DPBS five times for 5 min each, the cells were incu-
bated in goat anti-mouse IgG-FITC secondary antibody diluted 1:75
with 1.5% goat serum in DPBS for 60 min at RT in the dark. The cells
were then washed with DPBS five times for 5 min each and incu-
bated in 2% propidium iodide (PI) in DPBS for 15 min at RT in the
dark to stain the nucleus. A laser scanning confocal microscope
(Nikon, Melville, NY) was then used to image the cells. The
immunofluorescence microscopy images obtained were analyzed
for the quantification of smooth muscle a-actin in the cells using
ImageJ software as described previously [21–23]. Briefly, the fluo-
rescence intensity of the green color stained a-actin was measured.
Also, the fluorescence intensity of the background (spots in the
images where there are no cells) was measured. Once the inte-
grated density of the cell was calculated, the corrected total cell
fluorescence (CTCF) was determined using the following formula:
CTCF = Integrated density  (Area of selected cell Mean fluores-
cence of background readings). The CTCF determined was used as
a proxy for the amount of SM alpha-actin in the cells as described
previously [21–23]. For each group, at least 15 cells were used for
analysis.
2.8. Preparation of PAT–PEO coating on balloons
The PAT–PEO solution was prepared as described in the
Section 2.2 with 10 w/v% of PEO and 4.5 wt% of PAT. Angioplasty
balloon catheters (ev3 Inc., USA) of 2 mm in diameter  20 mm
in length were used for the experiments. The balloons were ini-
tially inflated with an air pressure of 6–8 atm. Then, the inflated
balloons were dipped in the prepared PAT–PEO solution (PAT
concentration – 4.5 mg/mL) for 1 min followed by transferring
them into an oven and heat treated in air at 50 C for 1 h. Theballoons were then taken out and dipped again in PAT–PEO
solution for 15 s followed by heat treatment in air at 50 C for
1 h. This step was again repeated twice.
2.9. Preparation of control DCBs using currently available DCB coating
combinations
The currently available coating combinations of DCBs include
PAT only (without any carriers), and drug-carrier combinations
such as PAT–urea, PAT–polysorbate/sorbitol, PAT–shellac, and
PAT–contrast agent [24]. In this study, five control DCBs were pre-
pared using these coating combinations. Except the control PAT
only (without any carrier), all other drug-carrier combination solu-
tions were prepared with a ratio of 1:1 (drug:carrier). The solvents
used for preparing these solutions are either ethanol only (for PAT
only and PAT–shellac) or ethanol:di-H2O (50:50, v/v, for PAT–urea,
PAT–polysorbate/sorbitol, and PAT–contrast agent). The concentra-
tion of PAT in all these solutions was kept as 4.5 mg/mL (the same
PAT concentration used in PEO formulation as listed in Section 2.8).
The balloons were coated with these solutions using the same dip
coating procedure as described in Section 2.8.
2.10. SEM imaging of PAT–PEO coated balloons and control DCBs
The PAT–PEO coated balloons (Section 2.8) and the five control
DCBs (Section 2.9) prepared were imaged using a SEM at three dif-
ferent positions including as-coated position, deflated position, and
inflated position. Also, a bare balloon without any coatings was
imaged in its inflated and deflated positions. An accelerated volt-
age of 1 kV was used to obtain the images at several different loca-
tions of the balloons.
2.11. Drug-elution studies of PAT–PEO coated balloons and control
DCBs
The PAT–PEO coated balloons and control DCBs were deflated
prior to drug-elution studies. Then, the deflated balloons were
immersed in 50 mL of PBS/T-20 solution and incubated in a circu-
lating water bath at 37 C. The balloons were removed from the
solution and transferred to a fresh PBS/T-20 solution at pre-
determined time points (30 s, 1 min, 2 min, 3 min, 4 min, 5 min,
and 7 min). After the 1 min time point, the balloons were inflated
with an air pressure of 6–8 atm and remained inflated for the time
points thereafter. After 7 min, the balloons were taken out and
sonicated in a 20 mL solution containing di-H2O and ethanol
(50:50, v/v) for 1 min to remove any residual drug present on the
balloon. All solutions collected were analyzed for the amount of
PAT released using HPLC.
2.12. Statistical analysis
All experiments conducted in this study were repeated at least
thrice using different film batches. The experimental data collected
in this study are presented as mean ± standard deviation. A one-
way analysis of variance (ANOVA) was used to determine the sta-
tistical significance at p < 0.05.
3. Results
3.1. Drug release from PAT–PEO films
Fig. 1A shows the percentage of PAT released at different time
point intervals for the four different groups of PAT–PEO films pre-
pared in this study. For PAT–PEO-10, the percentage of drug
released was less than 3% for up to 1 min. However, the remaining
Fig. 1. Percentage (A) and amount (B) of paclitaxel released from PAT–PEO-10, PAT–PEO-15, PAT–PEO-20, and PAT–PEO-25 films.
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1 min and 2 min. For PAT–PEO-15, only <4% of the drug was
released by 2 min. However, the remaining 90% of the drug was
released from this group of films between 2 min and 3 min. For
PAT–PEO-20, only 6% of the drug was released for up to 3 min.
However, the remaining 94% of the drug was released from
this group of films between 3 min and 5 min. Similarly, forTable 1C
Total amount of drug (lg/mm2) loaded in PAT–PEO films.
Sample group Drug loaded (lg/mm2)
PAT–PEO-10 4.6 ± 0.2
PAT–PEO-15 2.8 ± 0.5
PAT–PEO-20 3.4 ± 0.2
PAT–PEO-25 3.2 ± 0.5PAT–PEO-25, only <8% of the drug was released for up to 5 min.
However, the remaining 92% of the drug was released from this
group of films between 5 min and 7 min. These results strongly
demonstrated that the release of PAT from PEO films can be tai-
lored to deliver P90% of drug only at specific time intervals of
interest with <10% of the drug released at any other time points.
The total amount of PAT loaded in different groups of PAT–PEO
films is provided in Table 1C. Fig. 1B shows the amount of drug
released from four different groups of PAT–PEO films at different
time points. For PAT–PEO-10, a drug dose of 4.5 ± 0.2 lg/mm2
was released between 1 min and 2 min. Similarly, for PAT–PEO-
15, PAT–PEO-20, and PAT–PEO-25, the drug doses of 2.5 ± 0.5
lg/mm2, 3.2 ± 0.1 lg/mm2, and 3.0 ± 0.4 lg/mm2 were released
between 2–3 min, 3–5 min, and 5–7 min, respectively. Only a trace
amount of drug (<0.3 lg/mm2) was released from all these groups
of films at any other time points used in the study. Several clinical
studies in the literature have previously shown that a dose of
A) PEO-10 B) PEO-15 C) PEO-20 D) PEO-25
I) PEO-10 J) PEO-15 K) PEO-20 L) PEO-25
Film 
cross-secon
Film surface
Film 
cross-secon
Film
cross-secon
Film
cross-secon
Film 
cross-secon Film 
cross-secon
Film 
cross-seconFilm 
cross-secon
Film surface
Film surface
Film surface
Film surface
Film surface
Film surface Film surface
E) PAT-PEO-10 F) PAT-PEO-15 G) PAT-PEO-20 H) PAT-PEO-25
M) PAT-PEO-10 N) PAT-PEO-15 O) PAT-PEO-20 P) PAT-PEO-25
1 mm 1 mm 1 mm 1 mm
1 mm 1 mm 1 mm 1 mm
200 μm 300 μm 300 μm 300 μm
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Fig. 2. SEM images of surfaces (A–H) and cross-sections (I–P) of control PEO films and PAT–PEO films.
338 J.A. Anderson et al. / Acta Biomaterialia 29 (2016) 333–3512–3 lg/mm2 was effective in successfully inhibiting restenosis in
patients with peripheral vascular disease [12,24,25]. Based on
these literature, the doses of PAT released from PAT–PEO films pre-
pared in this study are clinically relevant for inhibiting restenosis.
3.2. SEM characterization of control PEO and PAT–PEO films
Fig. 2 shows the SEM images of surfaces and cross-sections of
control PEO and PAT–PEO films prepared in this study. The surfaces
of both the control PEO and PAT–PEO films were homogenous with
small fissures present on the surfaces (Fig. 2A–H). Also, all
PAT–PEO film surfaces (Fig. 2E–H) appeared smoother than their
corresponding control PEO film surfaces (Fig. 2A–D). The
cross-sections of control and PAT–PEO films were also homoge-
nous (Fig. 2I–P). Using SEM cross-sectional images, the thickness
of PEO-10, PEO-15, PEO-20, PEO-25, PAT–PEO-10, PAT–PEO-15,
PAT–PEO-20, and PAT–PEO-25 films was determined as
263 ± 64 lm, 342 ± 74 lm, 445 ± 77 lm, 517 ± 45 lm,
200 ± 43 lm, 322 ± 36 lm, 413 ± 18 lm, and 495 ± 26 lm, respec-
tively. Similar to the surface, the cross-sections of PAT–PEO films
(Fig. 2M–P) were smoother than that of their corresponding con-
trol PEO films (Fig. 2I–L). This could suggest that the PAT acted
as a filler by bridging the space between PEO polymeric chains tosmoothen the PAT–PEO films. Also, no PAT crystals were present
on the surface of PAT–PEO films (Fig. 2E–H). This suggested that
the PAT was successfully incorporated into the bulk of PEO films.
The cross-sections of PAT–PEO films also did not show the pres-
ence of PAT crystals (Fig. 2M–P). This suggested that the PAT was
molecularly dispersed in PEO with no crystals formed inside the
films irrespective of the type of PAT–PEO films prepared in this
study.
3.3. OSP characterization of control PEO and PAT–PEO films
Fig. 3 shows the 3D OSP topography images of control and PAT–
PEO films. These images show how the PEO crystals were dis-
tributed on the films. For the PEO-10 and PEO-15 films, the crystals
were loosely scattered with some crystals merging together. How-
ever, for the PEO-20 and PEO-25 films, the crystals were densely
packed with many of them merging together. For the PAT–PEO-
10 and PAT–PEO-15 films, the crystals were denser than that of
their corresponding control PEO films. For the PAT–PEO-20 and
PAT–PEO-25 films, the crystals were larger and denser than that
of their corresponding control PEO films. Table 1D shows the aver-
age surface roughness (Sa) of control PEO and PAT–PEO films.
Irrespective of control PEO or PAT–PEO films, the surface
A) PEO-10 B) PEO-15
C) PEO-20 D) PEO-25
E) PAT-PEO-10 F) PAT-PEO-15
G) PAT-PEO-20 H) PAT-PEO-25
Fig. 3. 3D optical surface profilometry images of control PEO films and PAT–PEO film surfaces.
Table 1D
Average surface roughness (Sa) of control PEO films and PAT–PEO films measured at
511 lm  510 lm field of view.
Sample group Sa (lm)
PEO-10 10.3 ± 2.8
PEO-15 11.2 ± 3.0
PEO-20 2.7 ± 0.3
PEO-25 2.3 ± 0.6
PAT–PEO-10 9.1 ± 2.4
PAT–PEO-15 9.3 ± 0.6
PAT–PEO-20 0.9 ± 0.1
PAT–PEO-25 1.3 ± 0.2
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mer was four times lower than that of the films prepared with 10and 15 w/v% of the polymer. This suggested that the films prepared
with higher w/v% (20 and 25) are smoother than that of the films
prepared with lower w/v% (10 and 15). Also, the surface roughness
of PAT–PEO films was lower than that of their corresponding
control-PEO films especially when the films were prepared with
higher w/v% (20 and 25). This result further emphasizes that the
addition of PAT improves the smoothness of the films.3.4. FTIR characterization of control PEO and PAT–PEO films
Fig. 4A shows the FTIR spectra of PEO and PAT in powder forms.
For the PEO powder (Fig. 4A-1), a large peak observed at 2878 cm1
was assigned for the C–H stretching of methylene groups in the
polymer. The peaks for scissoring, wagging, twisting, and rocking
A) FTIR spectra of PEO and PAT in powder forms 
B) FTIR of PAT-PEO and control PEO films
(2) PAT Powder
(1) PEO Powder
(1) PEO-10
(3) PEO-20
(4) PEO-25
(2) PEO-15
(5) PAT-PEO-10
(7) PAT-PEO-20
(8) PAT-PEO-25
(6) PAT-PEO-15
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Fig. 4. FTIR spectra of PEO and PAT in powder forms (A), and control PEO films and PAT–PEO films (B).
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1341 cm1, 1279 and 1241 cm1, and 961 and 841 cm1, respec-
tively. The three peaks observed at 1145, 1094, and 1059 cm1
were assigned for the C–O–C stretches of PEO. For the PAT powder
(Fig. 4A-2), the strong peaks for the C@O functionality of ester,
ketone, and amide groups were observed at positions 1733, 1704,
and 1645 cm1, respectively. Also, the peaks for the fingerprint
region of PAT were observed at 1241, 1176, 1071, 985, and704 cm1. The IR peaks and their positions of PEO and PAT powders
are in well agreement with the literature [26–29].
Fig. 4B shows the FTIR spectra of control PEO and PAT–PEO
films prepared in this study. The IR peaks and their positions
observed for all PEO films (Fig. 4B1–4) prepared in this study are
in excellent agreement with those of PEO powder. This indicated
that the incorporation of PAT did not affect the chemical structure
of PEO. Also, no IR peaks for PAT were observed in the spectra of
J.A. Anderson et al. / Acta Biomaterialia 29 (2016) 333–351 341PAT–PEO films (Fig. 4B5–8). This is also in agreement with the SEM
results (Section 3.2) that the PAT was incorporated into the bulk of
PEO films and was not present on the film surfaces.3.5. DSC characterization of control PEO and PAT–PEO films
Fig. 5A provides the DSC thermograms of PEO and PAT in pow-
der forms. The melting point of PEO powder was observed at 69 C
(Fig. 5A-1). For PAT powder, an endothermic melting peak was
observed at 221 C, which was immediately followed by an
exothermic decomposition peak at 231 C (Fig. 5A-2). For the con-
trol PEO films (Fig. 5B) and PAT–PEO films (Fig. 5C), there was no
significant shift in the melting point of PEO. This suggested that
the crystallinity of PEO was not affected either when the polymer
was made into a film or after the drug was incorporated into the
polymer film. Also, no peak for PAT was observed in any of the
PAT–PEO films. This is because of the less weight percentages of
drug loaded (1.5%, 1%, 0.75%, and 0.6%) in the polymer. Previous
studies have shown that the DSC peak for the drug loaded in the
polymer was absent when the wt% of drug loaded was lesser than
5% [30].3.6. Mechanical properties
Fig. 6 shows the stress–strain curves of control PEO and
PAT–PEO films prepared in this study. Elastic modulus is the mea-
sure of stiffness or rigidity of a material. A stiff material has a high
elastic modulus while a flexible material has a low elastic modulus.
In this study, after the incorporation of PAT in PEO, the PAT–PEO-
10 had a 23% higher elastic modulus than that of control PEO-10
(Table 1E). However, PAT–PEO-15, 20, and 25 had a 10%, 29%,
and 21% smaller elastic modulus than that of control PEO-15, 20,Temperature
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Fig. 5. DSC spectra of PEO and PAT in powder forms (and 25, respectively. These results suggested that the incorpora-
tion of drug in PEO increases the flexibility of films except for the
films prepared with 10 w/v% of polymer. Strain at break is the mea-
sure of ductility of materials. PAT–PEO-10, 15, 20, and 25 films
showed 140%, 29%, 74%, and 62% increased strain at break when
compared to their corresponding control PEO films (Table 1E). This
suggested that the incorporation of drug makes the films more
ductile. The peak load is directly related to yield strength, which
determines how much stress a sample can withstand before it
plastically deforms. The peak load for PAT–PEO-10 was signifi-
cantly greater (53%) than that of PEO-10 (Table 1E). However, for
the films prepared with 15, 20, and 25 w/v% of polymer, no signif-
icant difference in peak load was observed between control PEO
and PAT–PEO. These results suggested that the incorporation of
drug did not negatively affect the yield strength of the material.
Tensile strength is the maximum amount of stress that a material
can withstand before breaking. Hence, the greater the tensile
strength, the stronger the material. The tensile strength for PAT–
PEO-10 was significantly greater (97%) than that of PEO-10
(Table 1E). This suggested PAT–PEO-10 was stronger than PEO-
10. However, for the films prepared with 15, 20, and 25 w/v% of
polymer, no significant difference in tensile strength was observed
between control PEO and PAT–PEO. These results suggested that
the incorporation of drug did not negatively affect the strength of
the films.3.7. Characterization of PAT–PEO films post drug-elution study
The FTIR characterization of PAT–PEO-10, PAT–PEO-15,
PAT–PEO-20, and PAT–PEO-25 films collected after 1 min,
2.5 min, 3.15 min, and 6 min of drug-elution studies, respectively,
are provided in Fig. 7A. The peaks for the different functionalities (˚C)
Temperature (˚C)
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A), control PEO films (B), and PAT–PEO films (C).
Fig. 6. Stress–strain curves of PEO-10 and PAT–PEO-10 (A), PEO-15 and PAT–PEO-15 (B), PEO-20 and PAT–PEO-20 (C), and PEO-25 and PAT–PEO-25 (D).
Table 1E
Mechanical properties of control PEO films and PAT–PEO films.
Sample group Elastic modulus (MPa) Strain at break (%) Peak load (lbf) Tensile strength (MPa)
PEO-10 279 ± 21 1.5 ± 0.1 1.9 ± 0.2 3.3 ± 0.4
PEO-15 399 ± 39 2.4 ± 0.2 4.1 ± 0.5 5.3 ± 0.7
PEO-20 527 ± 72 1.9 ± 0.3 6.5 ± 1.2 6.5 ± 1.2
PEO-25 541 ± 43 2.1 ± 0.5 6.4 ± 0.1 5.5 ± 0.1
PAT–PEO-10 342 ± 34 3.6 ± 0.6 2.9 ± 0.4 6.5 ± 0.9
PAT–PEO-15 358 ± 49 3.1 ± 0.8 3.4 ± 0.4 4.7 ± 0.6
PAT–PEO-20 373 ± 46 3.3 ± 0.1 5.0 ± 0.8 5.3 ± 0.8
PAT–PEO-25 426 ± 58 3.4 ± 0.4 6.0 ± 0.8 5.4 ± 0.7
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948 cm1), and C–O–C (1081 cm1) were observed. This shows
that the chemical structure of PEO molecules was not altered in
the specimens (loose disintegrated films) collected after drug-
elution studies. These results suggested that the drug release from
PAT–PEO films occurred due to dissolution of films and not due to
biodegradation of polymer. A broad peak observed at 3370 cm1
was due to H2O molecules absorbed in the films during its immer-
sion in PBS/T-20 solution. Also, the peaks observed at 1645 cm1
and 1733 cm1 were assigned to the C@O functionality of amide
and ester groups of PAT delivered from the films, respectively.
Fig. 7B shows the DSC thermograms of PAT–PEO films collected
after the drug-elution studies. The thermograms showed two
peaks between 100 C and 125 C due to evaporation of free and
bonded water from the films. However, no melting peak for the
PEO crystals was observed at 65–70 C. This strongly suggested
that all PEO crystals were disintegrated under the conditions used
for drug-elution studies. These results further emphasized that the
drug was delivered from the PAT–PEO films due to dissolution of
films. Fig. 7C shows the real-time images of PAT–PEO films
obtained using phase contrast microscopy at different time points.Prior to its immersion in PBS/T-20, the films were intact as it
appeared mostly dark. The films absorbed most of the light and
reflected little to appear mostly dark. However, after immersion
in PBS/T-20, the PAT–PEO-10, 15, 20, and 25 films disintegrated
at 2, 3, 5, and 7 min, respectively, as it is evident from the images
which were mostly bright. The disintegrated films absorbed very
little light to appear mostly bright. Thus, these results were in
excellent agreement with FTIR and DSC to suggest that the drug
was delivered from PAT–PEO films mainly due to dissolution of
films.
3.8. Cell viability and proliferation
The viability and proliferation of SMCs treated with control PEO
films, PAT–PEO films, and no films (control wells) are provided in
Fig. 8. The cells in the control well containing no films proliferated
profusely from one time point to the other. It was interesting to
observe that all of the control PEO films significantly inhibited
(64–76% decrease) the growth of SMCs compared to that of control
wells. Also, for the control PEO films, an increase in the inhibitory
effect was observed as the w/v% of PEO increased. This suggested
C) Phase contrast microscopy images of PAT-PEO ﬁlms post drug-eluon study 
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Fig. 7. FTIR spectra (A), DSC spectra (B), and phase contrast microscopy images (C) of PAT–PEO films post drug-elution study.
Fig. 8. Viability and proliferation of human aortic smooth muscle cells for control wells (no films), control PEO films, and PAT–PEO films.
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344 J.A. Anderson et al. / Acta Biomaterialia 29 (2016) 333–351that the PEO alone (without the drug) can significantly inhibit the
growth of SMCs with greater inhibition rate observed for the films
with larger w/v% of the polymer. For PAT–PEO, all films
significantly inhibited (79–86% decrease) the growth of SMCs
when compared to that of the control well. Also, most of the
PAT–PEO films showed greater inhibitory effect (35–50% decrease)
than their corresponding control PEO films (day-5 in Fig. 8).Fig. 9. Fluorescence microscopy images (A-Z1) and aspect ratio (Z2) of human aortic smAlthough the wt% of drug was lesser (0.6%) in PAT–PEO-25, these
films showed maximum inhibitory effect when compared to that
of all other films prepared in this study. This could be due to the
combined effect of larger w/v% of polymer and the presence of
drug. Thus, these results demonstrated that the PAT–PEO films pre-
pared in this study effectively inhibited the growth of smooth mus-
cle cells.ooth muscle cells for control wells (no films), control PEO films, and PAT–PEO films.
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Fig. 9 shows the fluorescent microscopy images of the FDA
stained SMCs treated with control PEO films, PAT–PEO films, and
no films (control wells) at days 1, 3, and 5. In the control well,
the SMCs were elongated with its characteristic spindle-shape
and hill-and-valley morphology (Fig. 9A–C). The cells treated with
control PEO films mostly showed an irregular morphology on day-
1 (Fig. 9D,G,J,M). However, by day-5, the cells treated with control
PEO films started to show the normal spindle-shaped morphology
(Fig. 9F,I,L,O). This could suggest that PEO alone may not provide
the long-term inhibitory effect. Hence, the incorporation of anti-
proliferative agents is crucial for providing long-term inhibitory
effect to these films. Also, an increasing number of normal
spindle-shaped cells were observed for the films prepared with
lower w/v% (10 and 15) of polymer (Fig. 9F and I) than the films
prepared with higher w/v% (20 and 25) of polymer (Fig. 9L andFig. 10. Immunofluorescent microscopy images (A–I) and smooth muscle a-actin quanti
PEO films, and PAT–PEO films.O). This further emphasizes that higher w/v% of polymer has
greater inhibitory effect on SMCs. For all PAT–PEO films (Fig. 9P-
Z1), the cells displayed an uncharacteristic discoid (flat circular)
morphology for all time points used in this study. After 5 days,
the confluency of SMCs in the control well, control PEO-10, 15,
20, and 25 films were estimated as 90–95%, 50–60%, 50–60%, 20–
25%, and 20–25%, respectively. For all four PAT–PEO groups, very
few viable cells were only observed after day-5 with <10% conflu-
ency. These qualitative data are in excellent agreement with the
quantitative results described in the previous paragraph (Sec-
tion 3.8). The aspect ratio of SMCs treated with control PEO films,
PAT–PEO films, and no films (controls) are shown in Fig. 9Z2. On
day-1, the aspect ratio of the cells treated with PAT–PEO films
(1.3–1.5) and most PEO films (1.7–2.0 for PEO-15, 20, and 25) are
twice smaller than that of the controls (5.0 ± 2.0). The range of
aspect ratio of the cells in controls remained same for up to day-
5. Similarly, the range of aspect ratio of the cells treated withfication (J) of human aortic smooth muscle cells for control wells (no films), control
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Fig. 11. SEM images of bare balloon (A–F) and PAT–PEO coated balloon (G–O).
346 J.A. Anderson et al. / Acta Biomaterialia 29 (2016) 333–351PAT–PEO films remained same for up to day-5. However, the cells
treated with control PEO films showed an increase in aspect ratio
from day-1 to day-5. On day-5, there was no significant difference
observed in the aspect ratio of cells treated with control PEO films
and controls.
3.10. Cell phenotype
Smooth muscle (SM) a-actin is a cytoskeletal protein that is pri-
marily responsible for the motility, structure, and integrity of SMCs
[31]. A strong expression of SM a-actin is usually observed for well
growing SMCs [20]. Also, the a-actin filaments orient along the cell
axis in well growing SMCs. However, when the cells are damaged,
the expression of SM a-actin will be poor [20]. Also, the a-actin
filaments are typically disarranged in damaged SMCs. In this study,the immunofluorescence microscopy images of SMCs treated with
control PEO, PAT–PEO, and no films (control wells) are provided in
Fig. 10. The cells in the control well showed a stronger SM a-actin
expression (intense staining) with the a-actin filaments oriented
along the cell axis (Fig. 10A). This suggested the healthy state of
SMCs in control wells. However, the SM a-actin expression
was weaker (less intense staining) for all control PEO films
(Fig. 10B–E). Also, the cells showed a disarrangement of actin
filaments with an irregular orientation (Fig. 10B–E). This result
showed the inhibitory effect of control PEO films on SMC growth.
For PAT–PEO films, only very few cells showed the expression of
SM a-actin (Fig. 10F–I). Also, the expression was very weak with
a-actin filaments disarranged in circumferential orientation. This
result strongly suggested that PAT–PEO films effectively inhibited
the growth of SMCs. The quantification of smooth muscle a-actin
As-coated
posion
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Inﬂated
posion
A) PAT only B) PAT-urea D) PAT-shellac
C) PAT-
polysorbate/sorbitol E) PAT-contrast agent
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Fig. 12. SEM images of control drug-coated balloons prepared using PAT only (A, F, K), PAT–urea (B, G, L), PAT–polysorbate/sorbitol (C, H, M), PAT–shellac (D, I, N), and PAT–
iodixanol (E, J, O).
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The expression of SM a-actin in the cells treated with control
PEO films and PAT–PEO films was decreased by half when
compared to that of controls. No significant difference in the SM
a-actin was observed between the different groups of control
PEO films or PAT–PEO films. However, the expression observed
for all PAT–PEO films was significantly lesser than that of PEO-10
and PEO-15. Also, expression for PAT–PEO-25 was significantly
lesser than that of PEO-20 and PEO-25 as well. These results are
in agreement with the literature as PAT has been shown to
significantly decrease the expression of SM a-actin [32,33].
3.11. PAT–PEO coatings on balloons
Fig. 11A–C and D–F shows the SEM images of bare balloons
(without any coatings) in inflated and deflated positions, respec-
tively. These images show that the balloons were fully expanded
in its inflated position and were showing flaps in its deflated posi-
tion. Fig. 11G–I, J–L, and M–O shows the SEM images of PAT–PEO
coated balloons in as-coated, deflated, and inflated positions,
respectively. These images showed that the PAT–PEO coating was
smooth, uniform, and homogeneous on the balloon surface
(Fig. 11G–I). Also, the integrity of PAT–PEO coating on the balloons
was well maintained without any mechanical defects occurring
during inflation or deflation (Fig. 11J–O).
3.12. Currently available drug-carrier combination coatings on
balloons
Fig. 12A–E, F–J, and K–O shows the SEM images of control DCBs
prepared using currently available drug-carrier combinations in
as-coated, inflated, and deflated positions, respectively. These
images showed that these coatings are not smooth, nonuniform,
and inhomogeneous at several different spots on the balloon(Fig. 12A–E). Also, these coatings undergo mechanical defects dur-
ing balloon inflation or deflation to produce irregularities, ridges,
cracks, fissures, and rough textures (Fig 12F–O).
3.13. Drug release from PAT–PEO coating on balloon
For treatments using DCBs, the typical balloon tracking time is
from 30 s to 1 min. Once the balloon reaches the diseased site, a
time frame of 2–3 min is recommended for the treatment includ-
ing balloon inflation and drug delivery [24]. Hence, in this study,
we have considered the initial 1 min time as the typical time per-
iod for balloon tracking, and the following 3 min (from 1 min to
4 min) as the typical time period for treatment including inflation
and drug delivery. The total amount of PAT loaded on the PAT–PEO
coated balloons is 2.23 ± 0.31 lg/mm2. The currently available
DCBs carry drug doses in the range of 2 lg/mm2 to 3 lg/mm2
[24]. Hence, the total amount of PAT loaded on the balloons using
the PEO platform is clinically relevant for controlling neointimal
hyperplasia. The cumulative amount and percentage of PAT release
from PAT–PEO coatings are provided in Figs. 13A and 14A, respec-
tively. Only 15% of the total PAT loaded was released from the bal-
loons during the initial 1 min (typical balloon tracking time)
whereas 80% of the drug was released during 1 min to 4 min (typ-
ical treatment time period) and only 5% of the drug was present on
the balloons after 4 min as a residual drug.
3.14. Drug release from currently available drug-carrier combination
coatings on balloons
The total amount of PAT loaded on the balloons using currently
available drug-carrier combination coatings such as PAT only, PAT–
urea, PAT–polysorbate/sorbitol, PAT–shellac, and PAT–contrast
agent is 0.17 ± 0.11, 0.11 ± 0.03, 0.03 ± 0.01, 0.09 ± 0.02, and
0.05 ± 0.4 lg/mm2, respectively. The cumulative release and
Fig. 13. Cummulative PAT released (lg/mm2) from PAT–PEO coated balloons (A) and control drug-coated balloons (B–F).
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Fig. 13B–F and Fig. 14B–F, respectively. PAT only control showed
that only 26% of the total PAT loaded was released between
1 min and 4 min while 13% of the drug was released during the ini-
tial 1 min and 61% of the drug was retained on the balloon after
4 min. For PAT–urea, only 15% of the total drug loaded was
released between 1 min and 4 min while 13% was released during
the initial 1 min and 72% was retained on the balloon after 4 min.
For PAT–polysorbate/sorbitol, only 7% of the total drug loaded was
released between 1 min and 4 min while 36% was released during
the initial 1 min and 58% was retained on the balloon after 4 min.
For PAT–shellac, only 18% of the total drug loaded was released
between 1 min and 4 min while 40% was released during the initial
1 min and 42% was retained on the balloon after 4 min. For PAT–
contrast agent, only 24% of the total drug loaded was released
between 1 min and 4 min while 32% was released during the initial
1 min and 43% was retained on the balloon after 4 min.
4. Discussion
In this study, we have explored the use of polyethylene oxide
(PEO) films for applications in DCBs. PEO is a biocompatiblepolymer approved by U.S. Food and Drug Administration (FDA)
for internal use by humans [34]. PEO is used as an excipient in a
variety of pharmaceutical products that are administered orally
and parenterally in humans [34]. PEO is not a biodegradable poly-
mer. The half-life of PEO in blood circulation ranges from 18 min to
1 day as its molecular weight increased from 6000 to 190,000 [35].
The excretion of PEO from the body depends on its molecular
weight. The lower molecular weight PEO have been primarily
excreted through urine while the higher molecular weight
(>50,000) PEO have been excreted through feces [35]. Due to all
these significant advantages, PEO has been extensively used for
drug delivery applications.
PEO used for drug delivery is either uncrosslinked or cross-
linked depending on the applications [36,37]. The pure uncros-
slinked PEO is typically used in pharmaceutical products such as
oral tablets, bioadhesives, and osmotic pump tablets, while the
crosslinked PEO networks are used for applications in implants
and medical devices [36,37]. The reason that pure uncrosslinked
PEO is not commonly used in implants and medical devices is that
the polymer dissolves very quickly in water-based solutions.
Therefore, it is not possible to use this system for delivering drugs
for an extended period of time, which is the norm in most
Fig. 14. Percentage of PAT released from PAT–PEO coated balloons (A) and control drug-coated balloons (B–F).
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that makes the uncrosslinked PEO a promising material for appli-
cations in DCBs. Furthermore, the physiochemical properties of
PEO can be adjusted easily by varying the w/v% of polymer to tailor
the drug release at any specific time intervals between 1 min and
7 min, which is the time frame required for interventionalists to
carry out any basic or advanced clinical procedures involving
angioplasty as well as balloon-based drug delivery. In this study,
as evident from the SEM cross-sectional imaging, the thickness
(200 lm-500 lm) of the PAT–PEO films increases as the w/v%
(10–25%) of the polymer increases. The thicker the film, the longer
the time it takes to dissolve and slowly deliver the drug. This hasled to the delayed release of various PAT–PEO formulations pre-
pared in this study.
The PAT–PEO coated balloons and five control DCBs were pre-
pared using the same dip coating procedure and by keeping the
same concentration of PAT in the coating solutions. SEM images
showed that the PAT–PEO coating on the balloon was homoge-
neous and the coating integrity was well maintained without any
mechanical defects occurring during balloon inflation or deflation.
However, the coatings on the control DCBs were non-homogenous
and different types of mechanical defects were observed when the
balloons were inflated or deflated. This shows the use of PEO as a
mechanically robust coating for the balloons. The amount of PAT
350 J.A. Anderson et al. / Acta Biomaterialia 29 (2016) 333–351loaded on PAT–PEO coated balloons was 13 times, 20 times, 74
times, 24 times, and 45 times greater than the amount of PAT
loaded on PAT-only, PAT–urea, PAT–polysorbate/sorbitol, PAT–
shellac, and PAT–contrast agent control DBCs, respectively. This
signifies the use of a polymeric carrier such as PEO in carrying an
adequate amount of drug on the balloons. If a different coating pro-
cedure such as spray coating is employed, it is possible to load
more amount of PAT on the control DCBs. However, the accumula-
tion of more PAT directly on a material surface without a polymer-
based drug carrier could lead to the formation of loosely bound
PAT crystals to provide a burst release [17].
For DCB based therapy, a biphasic drug release profile with an
initial no drug release (up to 1 min) followed by an immediate
quick release of all the drug (between 1 min and 4 min) is needed.
The PAT–PEO film prepared in this study provided such drug
release profile with a minimal drug release (15%) during the ini-
tial 1 min followed by an immediate quick drug release (80%)
between 1 min and 4 min. The PAT–PEO films prepared undergo
controlled dissolution under physiological conditions to deliver
the drug only at specific time intervals that is suitable for DCB
based therapy. Such controlled dissolution property of PAT–PEO
films makes it a promising coating material for DCBs. For the con-
trols such as PAT only and PAT–urea, a sustained drug release was
observed, whereas for the controls such as PAT–polysorbate/sorbi
tol, PAT–shellac, and PAT–contrast agent, a biphasic release profile
with an initial burst release followed by a slow and sustained
release was observed. Such release profiles are not suitable for
DCB based therapy. The diffusion of drug from the coating and
the dissolution of carriers are considered to be primary mecha-
nisms for drug release from the controls used in this study. In this
study, 80% of the PAT loaded on the PAT–PEO coated balloons was
released between 1 min and 4 min (the typical time period of bal-
loon inflation and treatment). For the same time period, the % of
PAT released from PAT-only, PAT–urea, PAT–polysorbate/sorbitol,
PAT–shellac, and PAT–contrast agent control DBCs were 26%,
15%, 7%, 18%, and 24%, respectively. This further demonstrates
the role of PEO in controlling the delivery of drug from the
balloons.5. Conclusions
Various PAT–PEO films were developed in this study for appli-
cations in DCBs with a motivation to prevent initial drug loss dur-
ing balloon tracking and then to immediately deliver most of the
drug within a very short time period of balloon inflation and treat-
ment. The w/v% of PEO and wt% of PAT were varied in PAT–PEO
films to tailor the drug release in such a way that >90% of drug
was released only at specific time intervals. The SEM and FTIR col-
lectively showed that the PAT–PEO films developed were homoge-
neous and the PAT was molecularly dispersed in the PEO matrix.
DSC showed that the crystallinity of PEO was not affected after
the incorporation of PAT. The PAT–PEO films developed were flex-
ible and ductile with no effect observed on the yield or tensile
strengths of the films after drug incorporation. The FTIR, DSC,
and phase contrast microscopy characterizations of PAT–PEO films
post drug-elution study showed the dissolution of PEO under phys-
iological conditions as the primary mechanism for the delivery of
PAT. The cell culture studies showed that both the control PEO
and PAT–PEO films successfully inhibited the growth of SMCs with
a superior inhibitory effect observed for PAT–PEO films. The PAT–
PEO coating produced on the balloons was homogeneous and the
integrity of coating was well maintained without mechanical
defects occurring during balloon inflation and deflation. The drug
release studies showed that only 15% of the total PAT loaded was
released from the balloons during the typical balloon tracking timeperiod (initial 1 min) while 80% of the PAT was released during the
typical balloon treatment time period (from 1 min to 4 min), with
only 5% of the PAT present on the balloon as a residual drug after
4 min. Thus, this study demonstrated the use of PEO as an alternate
drug delivery platform for balloons.References
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